<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491409</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0130</org_study_id>
    <secondary_id>NCI-2020-04546</secondary_id>
    <secondary_id>2020-0130</secondary_id>
    <nct_id>NCT04491409</nct_id>
  </id_info>
  <brief_title>Perioperative Care in the Cancer Patient -1, ARCA-1 Study</brief_title>
  <official_title>ARCA-1 Study: Perioperative Care in the Cancer Patient -1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <brief_summary>
    <textblock>
      This study investigates the association of blood transfusions given around the time of&#xD;
      surgery (perioperative) with complications after surgery (postoperative), cancer progression,&#xD;
      and mortality after major oncologic non-cardiac surgery. The administration of blood products&#xD;
      is an important clinical therapy to treat life-threatening blood (hematological) disorders&#xD;
      (i.e. anemia, coagulation disorders or thrombocytopenia) in patients with cancer undergoing&#xD;
      major non-cardiac surgery. On the other hand, the unnecessary exposure of those patients to&#xD;
      blood products can be associated with the occurrence of unwanted severe complications and&#xD;
      potentially increase the risk of death. An accurate understanding of the short and long-term&#xD;
      outcomes, the patterns of blood transfusions, and the triggers of blood product&#xD;
      administration may help researchers design and test the safety of perioperative blood&#xD;
      transfusions in patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate if perioperative blood transfusions are associated with 1-year mortality.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the association of blood transfusion with postoperative complications, 30 days&#xD;
      mortality and cancer progression after major oncologic non-cardiac surgery.&#xD;
&#xD;
      II. To gain knowledge on prevalence and patterns of blood product administration worldwide,&#xD;
      the incidence and management of perioperative anemia and the incidence and treatment of&#xD;
      perioperative coagulopathies.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo standard of care treatment and their medical records are reviewed at 30 days&#xD;
      and at 1 year after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All causes of mortality</measure>
    <time_frame>1 year after major oncologic non-cardiac surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific mortality</measure>
    <time_frame>1 year after major oncologic non-cardiac surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the date of surgery to the date of progression or death whichever happened first, assessed at 1 year after major oncologic non-cardiac surgery</time_frame>
    <description>Kaplan-Meier method will be used to estimate the PFS, and the log-rank test will be used to evaluate the difference in PFS between the RBCT group and non-RBCT group. PFS rate at 1 year will be reported. Multivariable Cox proportional hazards models may be used to evaluate the effect of RBCT on PFS with the adjustment of other important covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 days mortality</measure>
    <time_frame>30 days after major oncologic non-cardiac surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of perioperative blood products transfusion</measure>
    <time_frame>During surgery and up to 2 weeks post surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (standard of care, medical chart review)</arm_group_label>
    <description>Patients undergo standard of care treatment and their medical records are reviewed at 30 days and at 1 year after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Undergo standard of care</description>
    <arm_group_label>Observational (standard of care, medical chart review)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Medical charts reviewed</description>
    <arm_group_label>Observational (standard of care, medical chart review)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient undergoing major cancer surgery with curative intent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing major cancer surgery with curative intent&#xD;
&#xD;
          -  Planned length of stay 24 hours after surgery or longer&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status (ASA) 1-4&#xD;
&#xD;
          -  Scheduled, non-emergency surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Palliative surgeries for metastatic disease (non-curative intent)&#xD;
&#xD;
          -  Patients undergoing surgery with minimum risk (&lt; 1%) of blood transfusion according to&#xD;
             each center practice (i.e. simple mastectomy, thyroidectomies or wide-local excisions)&#xD;
&#xD;
          -  Patients undergoing surgery under local anesthesia&#xD;
&#xD;
          -  Patients undergoing ambulatory surgery or planned hospital admission of less than 24&#xD;
             hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan P Cata</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan P. Cata</last_name>
    <phone>713-792-7452</phone>
    <email>jcata@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan P. Cata</last_name>
      <phone>713-792-7452</phone>
      <email>jcata@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Juan P. Cata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

